产品说明书
Rizatriptan
 |
同义名 : | - |
| CAS号 : | 144034-80-0 | |
| 货号 : | A138654 | |
| 分子式 : | C15H19N5 | |
| 纯度 : | 98% | |
| 分子量 : | 269.345 | |
| MDL号 : | MFCD03840591 | |
| 存储条件： |
粉末 Inert atmosphere,2-8°C 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : | - | |
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Rizatriptan, a quick and consistent 5-HT1B/1D agonist, is mainly used for the treatment of migraine[3]. In vitro studies, rizatriptan, with the lower maximum contractile response, would be less effective than sumatriptan in causing contraction of human isolated coronary artery[4]. Besides this, it was found that rizatriptan could not only cause about 10-fold effect of vasoconstriction in human isolated middle meningeal artery than in human coronary artery, but also more effectively promote the expression of 5-HT1B-receptors in middle meningeal artery than in coronary artery[5]. In vivo studies, rizatriptan could inhibit the expression of calcitonin gene-related peptide (CGRP) and cholecystokinin (CCK) in the rat migraine model induced by nitroglycerin, contributing to the mitigation of migraine[6]. In addition, rizatriptan, combined with inflammatory soup, has the ability of inducing nociception-related behaviours in Sprague-Dawley rats, as well as increasing Fos expression in the cortex and trigeminal pathway[7]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT00360282 | - | Completed | - | - | |
| NCT01332500 | - | Completed | - | - | |
| NCT01381523 | - | Completed | - | - | |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
3.71mL 0.74mL 0.37mL |
18.56mL 3.71mL 1.86mL |
37.13mL 7.43mL 3.71mL |
| 参考文献 |
|---|